A practical reference on pentapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-03 and is reviewed periodically as new material appears.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
=== Cryogenic refrigeration === The Topeka, Kansas shops of the Santa Fe Railway built five experimental refrigerator cars employing liquid nitrogen as the cooling agent in 1965. A mist induced by liquefied nitrogen was released throughout the car if the temperature rose above a pre-determined level. Each car carried 3,000 pounds (1,400 kg) of refrigerant and could maintain a temperature of minus 20 degrees Fahrenheit (−30 °C). During the 1990s, a few railcar manufacturers experimented with using liquid carbon dioxide (CO2) as a cooling agent. The move was in response to rising fuel costs and aimed to eliminate standard mechanical refrigeration systems that required periodic maintenance. The CO2 system can keep the cargo frozen solid for 14 to 16 days. Several hundred "cryogenic" refrigerator cars were placed in service to transport frozen foodstuffs. However, they failed to gain wide acceptance (due in part to the rising cost of liquid carbon dioxide).
=== Permittivity === Graphene's permittivity varies with frequency. Over a range from microwave to millimeter wave frequencies, it is approximately 3.3. This permittivity, combined with its ability to function as both a conductor and as an insulator, theoretically allows compact capacitors made of graphene to store large amounts of electrical energy.
=== Decreased MPV === Cytotoxic chemotherapy Hypersplenism Reactive thrombocytosis Iron-deficiency anemia Gilbert's syndrome Acquired Immunodeficiency Syndrome (AIDS) Wiskott–Aldrich syndrome X linked thrombocytopenia Crohn's disease Ulcerative colitis Aplastic anemia Megaloblastic anemia
== Add-ons == As a real-time trace gas analysis method based on mass spectrometry, PTR-MS has two obvious limitations: Isomers cannot be easily separated (for some it is possible by switching the reagent ions or by changing the reduced electric field strength in the drift tube) and the sample has to be in the gas phase. Countermeasures against these limitations have been developed in the form of add-ons, which can either be installed into the PTR-MS instrument or operated as external devices.
=== Pharmacokinetics === Upon oral administration, bismuth subcitrate undergoes partial dissolution in the acidic gastric environment, with the majority of the dose localizing in the stomach. Although the most of the dose remains unabsorbed, a small portion enters into systemic circulation, and serum concentration reaches (Cmax at 20–30 min) 16–80 ng/mL - levels that exceed the minimum inhibitory concentration for H. pylori (1–8 μg/mL). Co-administration with proton pump inhibitors (PPI) such as omeprazole or H2-antagonists such as famotidine increases serum and tissue concentrations of bismuth, possibly due to greater solubility and less rapid precipitation in less acidic gastric juice. In the small intestine, unlike the stomach, bismuth subcitrate does not form stable binding layers or antimicrobial reservoirs. At the more alkaline pH, colloidal particles aggregate and precipitate without significant further dissolution or interaction with epithelial or microbial targets. There is no conclusive evidence for microbiological impact of bismuth in the small intestine when administered at therapeutic doses. Upon entry into the large intestine (colon), bismuth is exposed to an anaerobic, sulfur-rich environment maintained by the gut microbiota. Here, it undergoes microbial methylation and sulfide complexation, yielding species such as trimethylbismuth (TMBi) and insoluble bismuth sulfide (Bi2S3), which is responsible for the black coloration of stool during therapy.
Sources: en.wikipedia.org
== Similar conditions == A food craving is an intense desire to consume a specific food, as opposed to general hunger. Similarly, thirst is the craving for water. A concept of food noise or food chatter has gotten more attention in the early 2020s since the advent of antiobesity indications for a class of medications called GLP-1 agonists (e.g., semaglutide). Food noise is a mental preoccupation with food in general (as opposed to one specific food) that is largely independent from physiological hunger but nonetheless is distracting for many people; it includes recurring thoughts about what one has or hasn't eaten in recent hours, what one would like to eat right now or "shouldn't" eat right now, and what one might be eating (or "should" avoid eating) in upcoming hours. Among people for whom these medications are effective in helping with weight loss, most express that the level of food noise in their mind is noticeably reduced. Even without these medications, some people may be able to reduce food noise by modifying their dietary patterns and exercise; this is more effective for some people than others. An expert panel convened in 2024 defined food noise as "Persistent thoughts about food that are perceived by the individual as being unwanted and/or dysphoric and may cause harm to the individual, including social, mental, or physical problems." The group also developed and conducted a rigorous, multi-step evaluation of an instrument to measure food noise (Ro-Allison-Indiana-Dhurandhar Food Noise Instrument, or RAID-FN).
=== Iron malabsorption === Iron from food is absorbed into the bloodstream in the small intestine, primarily in the duodenum. Iron malabsorption is a less common cause of iron-deficiency anemia, but many gastrointestinal disorders can reduce the body's ability to absorb iron. Different mechanisms may be present. In celiac disease, abnormal structural changes in the duodenum can decrease iron absorption. Abnormalities or surgical removal of the stomach can also lead to malabsorption by altering the acidic environment needed for iron to be converted into its absorbable form. If there is insufficient production of hydrochloric acid in the stomach, hypochlorhydria/achlorhydria can occur (often due to chronic H. pylori infections or long-term proton-pump inhibitor therapy), inhibiting the conversion of ferric iron to the absorbable ferrous iron. Bariatric surgery is associated with an increased risk of iron deficiency anemia due to malabsorption of iron. During a Roux-en-Y anastamosis, which is commonly performed for weight management and diabetes control, the stomach is made into a small pouch and this is connected directly to the small intestines further downstream (bypassing the duodenum as a site of digestion). About 17–45% of people develop iron deficiency after a Roux-en-Y gastric bypass.
Before Gagarin's flight, US President John F. Kennedy's support for America's piloted space program was lukewarm. Jerome Wiesner of MIT, who served as a science advisor to presidents Eisenhower and Kennedy, and himself an opponent of sending humans into space, remarked, "If Kennedy could have opted out of a big space program without hurting the country in his judgment, he would have." As late as March 1961, when NASA administrator James E. Webb submitted a budget request to fund a Moon landing before 1970, Kennedy rejected it because it was simply too expensive. Some were surprised by Kennedy's eventual support of NASA and the space program because of how often he had attacked the Eisenhower administration's inefficiency during the election. Gagarin's flight changed this; now Kennedy sensed the humiliation and fear on the part of the American public over the Soviet lead. Additionally, the Bay of Pigs invasion, planned before his term began but executed during it, was an embarrassment to his administration due to the colossal failure of the US forces. Looking for something to save political face, he sent a memo dated April 20, 1961, to Vice President Lyndon B. Johnson, asking him to look into the state of America's space program, and into programs that could offer NASA the opportunity to catch up. The two major options at the time were either the establishment of an Earth orbital space station or a crewed landing on the Moon. Johnson, in turn, consulted with von Braun, who answered Kennedy's questions based on his estimates of US and Soviet rocket lifting capability.
=== Non-specific inflammation === Factors allowing an abnormal immune response, once initiated, become permanent and chronic. These factors are genetic disorders which change regulation of the adaptive immune response. Genetic factors interact with environmental risk factors for RA, with cigarette smoking as the most clearly defined risk factor. Other environmental and hormonal factors may explain higher risks for women, including onset after childbirth and hormonal medications. A possibility for increased susceptibility is that negative feedback mechanisms – which normally maintain tolerance – are overtaken by positive feedback mechanisms for certain antigens, such as IgG Fc bound by rheumatoid factor and citrullinated fibrinogen bound by antibodies to citrullinated peptides (ACPA – Anti–citrullinated protein antibody). A debate on the relative roles of B-cell produced immune complexes and T cell products in inflammation in RA has continued for 30 years, but neither cell is necessary at the site of inflammation, only autoantibodies to IgGFc, known as rheumatoid factors and ACPA, with ACPA having an 80% specificity for diagnosing RA. As with other autoimmune diseases, people with RA have abnormally glycosylated antibodies, which are believed to promote joint inflammation.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.